Yes, Ozempic is a GLP-1 receptor agonist. Its active ingredient, semaglutide, is a synthetic version of the human GLP-1 hormone, designed to mimic and amplify what that hormone naturally does in your body. The FDA classifies Ozempic specifically as a “glucagon-like peptide 1 (GLP-1) receptor agonist,” sometimes also called a GLP-1 analog.
What GLP-1 Actually Does in Your Body
GLP-1 (glucagon-like peptide-1) is a hormone your gut releases after you eat. It signals your pancreas to produce insulin, tells your liver to stop dumping sugar into your bloodstream, and slows the speed at which food leaves your stomach. All of these effects work together to keep blood sugar from spiking after meals.
The problem is that natural GLP-1 breaks down in minutes. Semaglutide, the molecule inside Ozempic, is engineered to last far longer. A fatty acid attached to the molecule lets it hitch a ride on albumin, a protein in your blood, which extends its half-life to roughly 160 hours (about a week). That’s why Ozempic is injected just once per week rather than multiple times a day.
What Ozempic Is FDA-Approved to Treat
Ozempic carries three distinct FDA-approved uses, all related to type 2 diabetes:
- Blood sugar control: As an add-on to diet and exercise for adults with type 2 diabetes.
- Cardiovascular protection: To reduce the risk of major cardiovascular events (heart attack, stroke) in adults with type 2 diabetes and established heart disease.
- Kidney protection: To slow the decline of kidney function and reduce cardiovascular death in adults with type 2 diabetes and chronic kidney disease.
Ozempic is not FDA-approved for weight loss on its own. That approval belongs to Wegovy, which contains the exact same molecule (semaglutide) but at higher doses. The two drugs are essentially siblings: same active ingredient, different dosing and different labeled purposes.
Where GLP-1 Drugs Fit in Diabetes Treatment
GLP-1 receptor agonists like Ozempic have moved to the front of the line in diabetes care guidelines. The American Diabetes Association’s 2025 Standards of Care recommend GLP-1 receptor agonists as a preferred medication for adults with type 2 diabetes who also have heart disease, heart failure with preserved ejection fraction and obesity, or chronic kidney disease. In these situations, the guidelines call for using a GLP-1 RA regardless of where a patient’s blood sugar levels currently sit, because the cardiovascular and kidney benefits go beyond glucose control alone.
For adults with advanced kidney disease (very low kidney filtration rates), GLP-1 receptor agonists are specifically preferred over several other diabetes drug classes because they carry a lower risk of causing dangerous drops in blood sugar.
How Ozempic Works Differently From Insulin
A common point of confusion: Ozempic is not insulin. Insulin directly lowers blood sugar by pushing glucose into cells. Ozempic works one step upstream. By activating GLP-1 receptors, it prompts your pancreas to release more of your own insulin, but only when blood sugar is elevated. This glucose-dependent mechanism means it’s far less likely to cause hypoglycemia (dangerously low blood sugar) compared to insulin injections or certain older diabetes pills.
Ozempic also suppresses glucagon, a hormone that raises blood sugar, and slows gastric emptying so food enters your intestines more gradually. That slower digestion is part of why people feel fuller longer and why nausea is the most commonly reported side effect.
Side Effects Tied to the GLP-1 Mechanism
Because GLP-1 receptor agonists slow digestion, gastrointestinal side effects are the most frequent complaint. Nausea, vomiting, diarrhea, and constipation are all common, particularly during the first weeks of treatment or after a dose increase. These symptoms typically ease as your body adjusts.
Ozempic also carries an FDA boxed warning, the most serious type. In rodent studies, semaglutide caused thyroid C-cell tumors at doses comparable to what humans receive. Whether this translates to human risk remains unknown. Because of this uncertainty, Ozempic is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or a condition called Multiple Endocrine Neoplasia syndrome type 2. Symptoms to be aware of include a lump in the neck, difficulty swallowing, and persistent hoarseness.
Other GLP-1 Drugs on the Market
Ozempic is one of several GLP-1 receptor agonists available. Wegovy uses the same semaglutide molecule at higher doses for chronic weight management. Rybelsus is an oral tablet form of semaglutide for type 2 diabetes. Other GLP-1 receptor agonists include liraglutide (sold as Victoza for diabetes and Saxenda for weight loss) and dulaglutide (Trulicity). Newer combination drugs pair a GLP-1 with a second gut hormone called GIP, creating what’s known as a dual agonist, such as tirzepatide (Mounjaro, Zepbound).
All of these drugs activate the GLP-1 receptor. The differences come down to dosing frequency, whether they’re injected or swallowed, the specific conditions they’re approved for, and whether they also target additional hormone pathways.